These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8104074)

  • 21. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
    Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan.
    Kobayashi R; Ariga T; Nonoyama S; Kanegane H; Tsuchiya S; Morio T; Yabe H; Nagatoshi Y; Kawa K; Tabuchi K; Tsuchida M; Miyawaki T; Kato S
    Br J Haematol; 2006 Nov; 135(3):362-6. PubMed ID: 17032176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow transplantation in class 2 thalassemia patients.
    Giardini C; Galimberti M; Lucarelli G; Polchi P; Baronciani D; Angelucci E
    Bone Marrow Transplant; 1993; 12 Suppl 1():59-62. PubMed ID: 8374566
    [No Abstract]   [Full Text] [Related]  

  • 26. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.
    Bernaudin F; Souillet G; Vannier JP; Plouvier E; Lemerle S; Michel G; Bordigoni P; Lutz P; Kuentz M
    Bone Marrow Transplant; 1993; 12 Suppl 1():118-21. PubMed ID: 8374551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
    Dulley FL; Vigorito AC; Aranha FJ; Sturaro D; Ruiz MA; Saboya R; Macedo MC; Da Silva RL; Chamone DA; Mehta J; Bacigalupo A; De Souza CA
    Bone Marrow Transplant; 2004 Jan; 33(1):9-13. PubMed ID: 14578930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience.
    Ball LM; Lankester AC; Giordano PC; van Weel MH; Harteveld CL; Bredius RG; Smiers FJ; Egeler RM; Vossen JM
    Bone Marrow Transplant; 2003 Jun; 31(12):1081-7. PubMed ID: 12796787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group.
    La Nasa G; Argiolu F; Giardini C; Pession A; Fagioli F; Caocci G; Vacca A; De Stefano P; Piras E; Ledda A; Piroddi A; Littera R; Nesci S; Locatelli F
    Ann N Y Acad Sci; 2005; 1054():186-95. PubMed ID: 16339665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of murine beta-thalassemia by partial bone marrow chimerism: selective advantage of normal erythropoiesis.
    van den Bos C; Kieboom D; Wagemaker G
    Bone Marrow Transplant; 1993 Jul; 12(1):9-13. PubMed ID: 8374541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
    Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
    Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
    Erer B; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Galimberti M; Giardini C; Gaziev D; Maiello A
    Bone Marrow Transplant; 1996 Jul; 18(1):157-62. PubMed ID: 8832009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
    Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
    Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
    Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
    Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
    Khojasteh HN; Zakerinia M; Ramzi M; Haghshenas M
    East Mediterr Health J; 1999 May; 5(3):465-9. PubMed ID: 10793825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected complications after bone marrow transplantation in transfusion-dependent children.
    Saunders EF; Olivieri N; Freedman MH
    Bone Marrow Transplant; 1993; 12 Suppl 1():88-90. PubMed ID: 8374573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.